StockNews.AI
ARVN
StockNews.AI
106 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

1. Arvinas under investigation by Pomerantz LLP for potential securities fraud. 2. Company removed plans for two Phase 3 trials with Pfizer. 3. Arvinas plans to cut workforce by one-third to streamline operations. 4. Stock price dropped nearly 25% following announcements on May 1, 2025. 5. Investors encouraged to contact Pomerantz for further investigation details.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock price fell 24.84% due to critical announcements, indicating severe investor concern. Historical declines often continue when companies encounter legal or operational issues.

How important is it?

The potential for securities fraud and significant operational changes make this highly relevant to ARVN moving forward.

Why Short Term?

Immediate impacts are observable as investors react to fraud investigations and restructuring news. Similar situations have historically led to prolonged negative sentiment until clarity is achieved.

Related Companies

PFEBMYMRK
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, Arvinas issued a press release announcing that the Company and its development partners at Pfizer had “removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan.”  Arvinas’s Chief Executive Officer said that the “decision was made following a review of the totality of emerging information, including external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation.”  Arvinas also “[a]nnounced a reduction in workforce of approximately one-third across the Company to streamline operations across the organization and enable the efficient progression of the Company’s portfolio”, advising that “[t]he reduction is planned to be completed in the second quarter of 2025.”  On this news, Arvina’s stock price fell $2.39 per share, or 24.84%, to close at $7.23 per share on May 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News